Introduction {#s1}
============

The lifetime prevalence of epilepsy is 7.60 per 1,000 people ([@B5]), and more than 30% of patients with epilepsy have inadequate control of seizures ([@B12]). Because the percentage of patients with epilepsy who develop refractory epilepsy positively correlates with the number of seizures before treatment with antiepileptic drugs ([@B12]), it is important to reduce the number of seizures to prevent refractory epilepsy. Given these issues, we proposed that refractory epilepsy can be treated by focal cortical cooling (FCC) to 15°C to 25°C ([@B16]). However, little is known about the mechanism by which cooling inhibits seizures. In addition, treatment using FCC is highly invasive; therefore, new antiepileptic drugs involved in cooling but with different mechanisms of action are required to provide options to antiepileptic treatment using FCC.

Considering the antiepileptic effects of FCC, we focused on transient receptor potential (TRP) channels. The physiological function of TRP channels depends on their activation in a specific temperature range ([@B4]). The TRP melastatin 8 (TRPM8) channel is activated by cold (10°C--26°C) ([@B1]) or by TRPM8 agonists, such as icilin, a cooling compound with high affinity for TRPM8 ([@B15]). Icilin, a TRPM8 and TRP Ankyrin 1 agonist, reduced the amplitude of glutamatergic excitatory postsynaptic currents (EPSCs) in an electrophysiological study ([@B23]). These reports suggest that TRPM8 activation is involved in the suppressive effect of FCC on epilepsy. However, the antiepileptic effects of TRPM8 activation in the somatosensory cortex are unknown.

Penicillin G (PG)-induced experimental epilepsy is a common model of epileptic activity mediated by γ-aminobutyric acid (GABA)~A~-receptor antagonists ([@B21]; [@B6]; [@B2]; [@B11]), and PG injection at a dose of 1,200 IU is a model of epileptic focal seizures ([@B7]). Epileptiform discharges (EDs) have been detected both ictal and interictal electroencephalogram ([@B14]), and focal cortical dysplasias are associated with focal epileptic discharges of variable morphologies in the beta frequency band in addition to single epileptic spikes ([@B8]). Therefore, we hypothesized that if TRPM8 activation suppresses the increased power density of each band including the beta band, TRPM8 agonists may be new antiepileptic drug options. In this study, using electrocorticogram (ECoG) recordings, we examined whether TRPM8 activation by icilin suppresses EDs which were induced by administrated PG in the somatosensory cortex during anesthetized rats.

Methods {#s2}
=======

Male Sprague--Dawley rats aged 10 to 11 weeks and weighing 320 to 400 g (Japan SLC Inc. Fukuoka, Japan) were housed in groups of three rats per cage and kept under standard laboratory conditions in a temperature- and humidity-controlled room (23 ± 2°C, 55 ± 5%, respectively) on a 12-h light/dark cycle (lights on at 8:00 a.m). The animals had free access to food and water. The animal care and experimental procedures were approved by the Experimental Animal Care and Use Committee of Yamaguchi University School of Medicine, Japan. All experiments were performed in accordance with the guidelines of the Japan Association for Laboratory Animal Facilities of National University Corporations.

The animals were anesthetized with urethane (1.4 g/kg intraperitoneally) and immobilized using a stereotaxic apparatus. Each rat's body temperature was measured rectally and adjusted to 37 ± 2°C using a heating pad. We maintained cortical temperature at 35 ± 2°C ([**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}). We created two burr holes measuring 1.0-mm diameter, one for the ECoG recording and one for the reference electrode, above bilateral sensorimotor cortices and the cerebellum using the following coordinates relative to the bregma and the lambda: posterior, 2.0 mm; lateral, 4.0 mm; and posterior, 2.0 mm. We also placed a thin thermocouple (IT-24; Physitemp, Tokyo, Japan), and two ECoG and reference electrodes in bilateral somatosensory cortices and the cerebellar area between the skull and dura. We placed a ground electrode in the tail. A small slit in the dura was made to insert an injection cannula (0.4 mm diameter × 40 mm length, and 3 µl volume; EIM-40; Eicom, Kyoto, Japan). PG (Meiji, Tokyo, Japan) and icilin (Merck KGaA, Darmstadt, Germany) were injected into the same location *via* the same route without mixing, using the following procedure: first, we used a 10-µl Hamilton syringe with a 26-gauge removable needle (1701RN-7758-02; Hamilton, Reno, NV). The 1-µl inner cavity of the removable needle was filled with 1 µl of PG (dissolved in 0.9% saline at 400 IU/µl). The 10-µl syringe body was filled with 1 µl of PG and 8.8 µl of icilin, which were separated by 0.2 µl of air. PG and N-(3-aminopropyl)-2-\[(3-methylphenyl) methoxy\]-N-(2-thienylmethyl)-benzamide hydrochloride (AMTB) were also separated by 0.2 µl of air. Second, the injection cannula and Hamilton syringe were connected through a Teflon tube (JT-10; 50-cm-long, 4-µl volume; Eicom). After the PG filled in the Hamilton syringe reached the tip of the injection cannula through the Teflon tube, the injection cannula was inserted to a depth of 1 mm from the brain surface. PG was administered intracortically for 10 min at a rate of 0.1 µl/min using a microinjection pump (ESP-64, Eicom, Japan), beginning 60 min after the start of the ECoG recording.

Icilin \[dissolved in 1% dimethyl sulfoxide (DMSO: Merck KGaA) in saline\] was administered intracortically for 10 min, with icilin administration starting 90 min after the PG injection, at a rate of 0.1 µl/min using a microinjection pump. The spike amplitudes of PG-induced EDs with reference to baseline were averaged every 10 min. Because the duration in which the ED amplitude was statistically suppressed was considered the period of drug efficacy, we selected a duration from 100 to 110 min after PG injection as the postinjection period ([**Supplementary Figure S2**](#SM3){ref-type="supplementary-material"}). ECoG activities with preadministration of AMTB were averaged over 10 min, from 70 to 80 min after PG injection.

ECoGs were amplified by a bio-amplifier (EX-1; Dagan Corporation, Minneapolis, MN) and continuously recorded for 4 h (1 h for ECoG stabilization and 3 h for acquisition of PG-induced EDs) using an analogue/digital converter at a sampling rate of 2 kHz (PowerLab 8/30; AD Instruments, Castle Hill, Australia). The conditions for recording ECoGs were as follows: low-frequency filter, 0.1 Hz; high-frequency filter, 10 kHz; notch filter: off. We measured the following four parameters: spike amplitude ([@B22]), duration ([@B22]), power density of each band ([@B11]), and firing rate ([@B22]) using Lab Chart Pro v. 8.1.5 (AD Instruments). The spike amplitude and duration detected in each rat were automatically calculated and measured using this software, and after the ECoG was fast Fourier-transformed, the absolute band power was calculated for prominent ECoG spectral bands (delta, 1--4 Hz; theta, 4--9 Hz; alpha, 9--14 Hz; beta 1, 14--24 Hz; and beta 2, 24--30 Hz). To clarify whether icilin affects the ECoG in all frequency bands or in a specific frequency band, we calculated the power density of ECoG in each frequency bands during basal activity: the 10-min period just before PG injection, preinjection: control group for the efficacy evaluation, and postinjection: the 10-min period just after the end of the latest injection. Spike duration was defined as a spike wave with a duration \< 100 ms ([@B11]). In this study, the rats were used independently in each group. Regarding the inhibition of TRPM8 by AMTB, we evaluated ECoG recordings using three different doses of AMTB for the treatment groups, namely, PG + 0.3 mM AMTB + 3.0 mM icilin, PG + 1.0 mM AMTB + 3.0 mM icilin, and PG + 3.0 mM AMTB + 3.0 mM icilin, and for the control groups, which received PG + 0.3 mM AMTB + 1% DMSO, PG + 1.0 mM AMTB + 1% DMSO, and PG + 3.0 mM AMTB + 1% DMSO.

All results are expressed as mean ± standard error of the mean (SEM). Differences between preinjection and postinjection in the same groups for spike amplitude, spike duration, and firing rate were assessed using paired *t*-tests. Differences in spike amplitude, spike duration, and firing rate between groups were assessed by Dunnett's test, with *p* \< 0.05 indicating significance. Differences between groups for the power density of each spectrum were assessed by one-way analysis of variance (ANOVA) followed by Tukey's test, with *p* \< 0.05 indicating significance.

Results {#s3}
=======

Suppressive Effects of Icilin on Epileptiform Discharges {#s3_1}
--------------------------------------------------------

[**Figure 1A--D**](#f1){ref-type="fig"} shows examples of changes in ED, cortical temperature, and a typical ECoG preinjection and postinjection. The EDs were induced by the intracortically PG injection. There were no significant differences between EDs preinjection and postinjection of 1% DMSO ([**Figure 1E and F**](#f1){ref-type="fig"}). There was a tendency for decreases in spike amplitude and duration after 0.3-mM icilin injection ([**Figure 1E and F**](#f1){ref-type="fig"}), but the effect was not significant. There was a significant reduction in both spike amplitude and duration with 1.0 mM icilin ([**Figure 1E and F**](#f1){ref-type="fig"}), but we saw no influence on firing rate ([**Figure 1G**](#f1){ref-type="fig"}) or power density in each frequency band ([**Figure 1H**](#f1){ref-type="fig"}). Compared with preinjection, 3.0 mM icilin eliminated all EDs for only a few minutes ([**Figure 1D**](#f1){ref-type="fig"}) and significantly suppressed PG-induced spike amplitude, duration, firing rate, and power density in each frequency band in the EDs ([**Figure 1E--H**](#f1){ref-type="fig"}). In particular, 3.0-mM icilin injection decreased the power density in each frequency band to the level of basal activity ([**Figure 1H**](#f1){ref-type="fig"}).

![Suppressive effects of icilin on components of EDs. Examples of changes in ED and cortical temperature with **(A)** PG + 1% DMSO, **(B)** PG + 0.3 mM icilin, **(C)** PG + 1.0 mM icilin, **(D)** PG + 3.0 mM icilin. **(A--D)** Each bar indicates the duration of ECoG analysis during basal activity, and preinjection and postinjection. **(E)** Spike amplitude, **(F)** spike duration, and **(G)** firing rate during the preinjection (black) and postinjection (gray) periods with PG + 1% DMSO (*n* = 7), PG + 0.3 mM icilin (*n* = 7), PG + 1.0 mM icilin (*n* = 7), and PG + 3.0 mM icilin (*n* = 7). **(H)** ECoG power during basal activity (white), and the preinjection (black) and postinjection (gray) periods for each frequency band. The results are shown as mean ± SEM; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, paired *t*-test; ^†^ *p* \< 0.05, ^††^ *p* \< 0.01, ^†††^ *p* \< 0.001, one-way analysis of variance followed by Tukey's test; ^\#\#^ *p* \< 0.01 vs PG + 1% DMSO group, followed by Dunnett's test. ED, epileptiform discharge; PG, penicillin G; DMSO, dimethyl sulfoxide; ECoG, electrocorticogram; SEM, standard error of the mean.](fphar-10-00652-g001){#f1}

Suppressive Effects of Transient Receptor Potential Melastatin 8 Activation on Epileptiform Discharges {#s3_2}
------------------------------------------------------------------------------------------------------

[**Figure 2A--D**](#f2){ref-type="fig"} shows examples of changes in ED, cortical temperature, and a typical ECoG preinjection and postinjection. The suppressive effect of 3.0 mM icilin on PG-induced EDs such as increased spike amplitude, duration, firing rate, and power density in each frequency band ([**Figure 1E--H**](#f1){ref-type="fig"}) was also detected when administering 3.0 mM icilin just after 1% DMSO injection ([**Figure 2E--H**](#f2){ref-type="fig"}). However, the suppressive effect of 3.0 mM icilin on EDs was antagonized when N-(3-aminopropyl)-2-\[(3-methylphenyl) methoxy\]-N-(2-thienylmethyl)-benzamide hydrochloride (AMTB), a selective TRPM8 inhibitor, was administered at a dose of 3.0 mM just before icilin injection ([**Figure 2E--H**](#f2){ref-type="fig"}). These results suggested that TRPM8 activation suppressed EDs.

![Antagonistic effect of AMTB on icilin-mediated ED suppression. Examples of changes in ED and cortical temperature with **(A)** PG + 1% DMSO + 3.0 mM icilin, **(B)** PG + 0.3 mM AMTB + 3.0 mM icilin, **(C)** PG + 1.0 mM AMTB + 3.0 mM icilin, and **(D)** PG + 3.0 mM AMTB + 3.0 mM icilin. **(A--D)** Each bar indicates the duration of ECoG analysis during basal activity, and preinjection and postinjection. **(E)** Spike amplitude, **(F)** spike duration, and **(G)** firing rate during the preinjection (black) and postinjection (gray) periods with PG + 1% DMSO + 3.0 mM icilin (*n* = 6), PG + 0.3 mM AMTB + 1% DMSO (*n* = 5), PG + 0.3 mM AMTB + 3.0 mM icilin (*n* = 5), PG + 1.0 mM AMTB + 1% DMSO (*n* = 5), PG + 1.0 mM AMTB + 3.0 mM icilin (*n* = 5), PG + 3.0 mM AMTB + 1% DMSO (*n* = 5), PG + 3.0 mM AMTB + 3.0 mM icilin (*n* = 6). **(H)** ECoG power during basal activity (white), and preinjection (black) and postinjection (gray) periods for each frequency band. The results are shown as mean ± SEM; \*\**p* \< 0.01, paired *t*-test; ^†^ *p* \< 0.05, ^††^ *p* \< 0.01, ^†††^ *p* \< 0.001, one-way analysis of variance followed by Tukey's test; ^\#^ *p* \< 0.05 vs PG + 1% DMSO + 3.0 mM icilin group, followed by Dunnett's test. AMTB, N-(3-aminopropyl)-2-\[(3-methylphenyl) methoxy\]-N-(2-thienylmethyl)-benzamide hydrochloride; ED, epileptiform discharge; PG, penicillin G; DMSO, dimethyl sulfoxide; SEM, standard error of the mean.](fphar-10-00652-g002){#f2}

Discussion {#s4}
==========

To our knowledge, ours is the first report to show the suppressive effects of TRPM8 activation on EDs using ECoG analysis in a PG-induced epilepsy model in rats. Icilin decreased the spike amplitude, spike duration, firing rate, and all frequency bands in PG-induced EDs. These suppressive effects of 3.0 mM icilin were antagonized when AMTB was administered just before icilin injection. In this study, we did not use decreased brain surface temperature to activate TRPM8, which allowed us to reveal that TRPM8 activation by icilin suppressed the power density of each ED spectrum to the basal activity level ([**Figure 1H**](#f1){ref-type="fig"}). FCC of the somatosensory motor area from 20°C to 15°C did not suppress normal function ([@B7]), supporting our finding of the suppressive effects of icilin on PG-induced EDs without excessive suppression of basal ECoG activity.

The increase in power induced by PG in all bands was responsible for disinhibition of synchronous firing activity in the cortex, consistent with previous studies ([@B3]; [@B11]). An *in vivo* study showed that all bands (delta, theta, alpha, beta 1, and beta 2) in the power density spectra of PG-induced EDs were suppressed by FCC to 15°C ([@B11]), a temperature at which the TRPM8 channel is activated ([@B19]). In addition, a clinical report showed that FCC to 15°C also decreased the amplitude of EDs detected in an intraoperative study of patients with refractory epilepsy ([@B16]). The firing rate of action potentials was also significantly lower after perfusion of 3.0 mM icilin ([**Figure 1G**](#f1){ref-type="fig"}) and cooling to 15°C ([@B18]). Administrated intracortically icilin at the dose of 3 µM suppressed the amplitude of EDs in C57BL/6 mouse, while administrated intracortically icilin at the dose of 3 µM did not affect the ECoG for PG-induced EDs in TRPM8 knockout (TRPM8KO) mouse (data not shown). In contrast with our conclusion, the previous report was concluded that icilin can modulate glutamatergic neurons in the brain through a TRP-independent pathway, regardless of whether the neurons are stimulated intracellularly or by hyperactive microcircuitry ([@B20]). Moreover, it was reported that AMTB inhibited voltage gated sodium channels ([@B25]). However, we revealed that the suppressive effect of high concentrated icilin on EDs was antagonized when AMTB, a TRPM8 inhibitor, was administered just before icilin injection ([**Figure 2E--H**](#f2){ref-type="fig"}). We additionally examined that the effect of AMTB on the ECoG for basal activity and PG-induced EDs using C57BL/6 mice and TRPM8KO mice. Administrated intracortically AMTB at the dose of 3 µM did not affect the ECoG for basal activity and PG-induced EDs in C57BL/6 mice and TRPM8KO mice (Data not shown). These reports indicate that the suppressive effects of TRPM8 activation by icilin on focal cortical EDs are largely consistent with the reported physiological function of FCC. Moreover, the report by Pezzoli and our findings may suggest that the suppressive effects of icilin on EDs are not only TRPM8 activation but also through a TRP-independent pathway.

Our finding that 3.0 mM icilin reduced the duration of EDs does not agree with a report that showed that 50 µM icilin had no effect on action potential duration using normal cortical isolated neurons ([@B20]). In contrast, our results describe the suppressive effects of high concentrated icilin on PG-induced EDs in the cortical region of rats when the neural network is maintained and cortical cells are abnormally synchronized by PG. These differences in measurement conditions could lead to the different results between the published data and our findings.

Icilin at the dose of 3.0 mM eliminated all EDs only for a few minutes ([**Figure 1D**](#f1){ref-type="fig"}), whereas no EDs were detected when 3.0 mM icilin was administrated intracortically 30 min before PG injection ([**Supplementary Figure S4**](#SM5){ref-type="supplementary-material"}), and the previous study shown continuously eliminates EDs during the treatment of FCC at 15°C ([@B11]). The duration of elimination of EDs likely differs between TRPM8 activation and FCC mainly because of a difference in the number of suppression mechanisms for EDs. Icilin suppressed the amplitude of neuronal firing generated at a given voltage in layer V pyramidal neurons ([@B20]), whereas menthol, a TRPM8 agonist, had a distinct impact on TRPM8 currents and TRPM8-mediated calcium signals in excitable cells ([@B10]). Icilin reduced the amplitude of primary afferent-evoked glutamatergic excitatory postsynaptic currents (EPSCs) and increased miniature EPSC rates in subpopulations of lamina I and II neurons ([@B23]), whereas menthol produced a concentration-dependent extension of spontaneous GABA~A~ receptor-mediated inhibitory postsynaptic currents in native periaqueductal gray neurons ([@B13]). These reports indicate that TRPM8 activation temporarily but strongly suppresses EDs.

In addition, several reports have shown effects of FCC on EDs at a temperature range that induces TRPM8 activation. The amplitude of EDs induced by kainic acid, kainate type glutamate receptor agonist, was immediately decreased after cooling and continued to decrease as the temperature of the cortex was lowered ([@B9]). Compared with 33°C, cooling to 20°C markedly reduced neurotransmitter release in rat hippocampal slices ([@B24]), and FCC to 15°C decreased the extracellular concentrations of glutamate ([@B16]). In contrast, the reduction in the extracellular GABA by the treatment of FCC at 15°C did not correlate with the reduction of power density in ECoG ([@B17]). These reports suggested that the reduction in the extracellular glutamate may have contributed to further suppression of EDs. Therefore, a more understanding of the antiepileptic action by icilin requires further study whether icilin modulate the concentration of extracellular glutamate.

Our findings may suggest that TRPM8 activation is involved in the suppressive effect of FCC on EDs. However, because urethane dramatically changes the background electroencephalogram, a more understanding of the antiepileptic effect by icilin requires further studies, the effects of icilin on seizures in awake subjects using TRPM8KO mice and rats are recorded ECoG by anesthetized with inhalation. In addition, a more complete understanding of this antiepileptic effect requires further studies: the expression of TRPM8 channels in the somatosensory cortex, the effects of TRPM8 inactivation under cooling conditions on EDs, the effects of TRPM8 activation on sensorimotor functions, and the effects of TRPM8 activation in chronic phase on EDs using TRPM8KO mice. In conclusion, the role of TRPM8 activation by icilin in suppressing EDs may be the basis for developing new drug treatment for patients with epilepsy.
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